Sabra Health Care REIT, Inc. (SBRA)
NASDAQ: SBRA · Real-Time Price · USD
17.02
-0.08 (-0.47%)
At close: Dec 27, 2024, 4:00 PM
17.00
-0.02 (-0.12%)
After-hours: Dec 27, 2024, 7:09 PM EST
Sabra Health Care REIT Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for SBRA stock have an average target of 19.5, with a low estimate of 18 and a high estimate of 21. The average target predicts an increase of 14.57% from the current stock price of 17.02.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for SBRA stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 5 | 5 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 5 | 3 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 10 | 11 | 9 | 9 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy → Hold Downgrades $20 | Buy → Hold | Downgrades | $20 | +17.51% | Dec 5, 2024 |
| Scotiabank | Scotiabank | Hold Maintains $17 → $18 | Hold | Maintains | $17 → $18 | +5.76% | Oct 11, 2024 |
| Wells Fargo | Wells Fargo | Hold → Buy Initiates $16 → $20 | Hold → Buy | Initiates | $16 → $20 | +17.51% | Oct 1, 2024 |
| Citigroup | Citigroup | Hold → Strong Buy Upgrades $17 → $20 | Hold → Strong Buy | Upgrades | $17 → $20 | +17.51% | Sep 13, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $16 → $18 | Strong Buy | Maintains | $16 → $18 | +5.76% | Sep 4, 2024 |
Financial Forecast
Revenue This Year
699.50M
Revenue Next Year
745.63M
from 699.50M
Increased by 6.59%
EPS This Year
0.52
from 0.06
Increased by 777.19%
EPS Next Year
0.70
from 0.52
Increased by 33.88%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 741.6M | 830.1M | 930.7M | |||
| Avg | 699.5M | 745.6M | 806.1M | |||
| Low | 648.6M | 682.1M | 707.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 18.7% | 24.8% | |||
| Avg | - | 6.6% | 8.1% | |||
| Low | - | -2.5% | -5.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 0.58 | 0.76 | 0.85 |
| Avg | 0.52 | 0.70 | 0.76 |
| Low | 0.47 | 0.59 | 0.67 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 870.6% | 44.9% | 21.7% |
| Avg | 777.2% | 33.9% | 9.0% |
| Low | 690.6% | 12.7% | -4.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.